← Back to Clinical Trials
RecruitingNCT07050381

The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionArteriovenous Malformation of Central Nervous System
SponsorThe First Affiliated Hospital with Nanjing Medical University
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment200
SexALL
Min AgeN/A
Max AgeN/A
Start Date2025-06-13
Completion2025-08-31

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

AVMs have been reported to rupture at a formidable annual rate of 2% to 3% at natural progression, often resulting in longterm neurological deficits and poor functional outcomes.The reported risk of hemorrhagic presentation in patients with AVMs is 41% to 65%. While many studies suggest a correlation between higher hemorrhage risk and the concurrent presence of AVM and aneurysms, few authors have focused specifically on flow-related aneurysms alone. In many instances, the source of rupture is also unclear. Meta-analysis from 2016 suggested that 49.2% of hemorrhages were secondary to aneurysm rupture, 45% from AVM rupture, and 5.7% were undetermined.In a study of 302 patients, of which 52.6% had a hemorrhagic presentation, demonstrated a significant increase in rate of hemorrhage in those with flow-related aneurysms. Thus, it is necessary to figure out risk factors related to ruptured flow-related aneurysms in pAVM.

Eligibility Criteria

Inclusion Criteria: 1. pAVM with flow-related aneurysms were identified by DSA, and subarachnoid hemorrhage was confirmed by CT 2. No history of stroke, Marfan syndrome, polycystic kidney disease Exclusion Criteria: 1. pAVM without flow-related aneurysms 2. Absence of clinical data

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology